Table 5 Comparison of the rate of SVR12 and adherence to DAAs
Reference (published year) | Study design | Genotype | Medications | Adherence assessment | SVR12 (%) | Adherence (%) |
|---|---|---|---|---|---|---|
Present study | Retrospective | 1 and 2 | Various kinds of DAA | Pill count | 99.6% (265/266) | Adherent (defined as ≥95% of pill count): 99.0% (397/401) Adherent (defined as ≥90% of pill count): 99.3% (398/401) |
Retrospective analyses of clinical practice | ||||||
9 (2016) | Retrospective | 1–3 | Various kinds of DAA | Patient report | 93.2% (124/133) | Adherent (defined as 100% of adherence): 79.1% (102/129) |
12 (2017) | Retrospective | 1–4 | Various kinds of DAA | PDC from pharmacy record b | Specialty pharmacy 92.9% (156/168) | Adherent (defined as ≥80% of PDC): 100% (206/206) |
Nonintegrated pharmacies 88.6% (39/44) | Adherent (defined as ≥80% of PDC): 97% (55/57) | |||||
16 (2016) | Retrospective | 1 a | SOF/LDV | PDC from pharmacy record b | All subjects: 95.3% (928/974) Patients with adherence of ≥90%: 96.3% (621/645) <90%: 95.0% (301/317) <50%: 50.0% (6/12) | 100% of PDC: 65.7% (632/962) ≥90% of PDC: 67.0% (645/962) ≥80% of PDC: 67.8% (653/962) |
2 or 3 | SOF+RBV | PDC from pharmacy record b | All subjects: 88.2% (585/663) Patients with adherence of ≥90%: 89.9%(561/624) <90%: 67.6% (23/34) <50%: 20.0% (1/5) | 100% of PDC: 92.1% (606/658) ≥90% of PDC: 94.8% (624/658) ≥80% of PDC: 98.3% (647/658) | ||
17 (2016) | Retrospective | 1 a | SOF, SOF/LDV, simeprevir | Patient report | 90.4% (225/249) | Adherent (defined as 100% of adherence): 97.0% (360/371) |
18 (2017) | Retrospective | 1–3 | Various kinds of DAA | PDC from pharmacy record b | 94.1% (350/372) | Mean PDC: 98.7% Adherent (defined as ≥95% of PDC): 98.9% (358/362) |
Analyses of phase 2 and/or 3 clinical trials | ||||||
15 (2016) | Pooled analysis of phase 2-3 studies | 1–6 | SOF+RBV±LDV | Pill count | All subjects: 84.4% (2134/2528) Patients with adherence of ≥80%: 85.4% (1820/2131) <80%: 79.1% (314/397) | Mean: 91.3% Adherent (defined as ≥80% of doses): 84.3% (2131/2528) |
Pooled analysis of phase 2-3 studies | 1–6 | SOF/LDV | Pill count | All subjects: 96.5% (1441/1493) Patients with adherence of ≥80%: 97.1% (1394/1436) <80%: 82.5% (47/57) | Mean: 97.5% Adherent (defined as ≥80% of doses): 96.2% (1436/1493) | |
19 (2016) | Pooled analysis of phase 3 studies | 1 | SOF/ LDV±RBV | Pill count | 96.7% (1888/1952) | Adherent (defined as ≥80% of doses): 92.3% (1802/1952) |
20 (2016) | Pooled analysis of phase 3 studies | 1–6 | SOF/velpatasvir | Pill count | 98.1% (1015/1035) | Adherent (defined as ≥90% of doses): 95.8% (992/1035) |
21 (2016) | Phase 2a study | 1 | SOF/LDV | MEMS Pill counts Patient report | 96.6% (58/60) | MEMS: mean 96.7% Pill counts: mean 98.2% Patient report: mean 99.3% |